Education
About Us
Working with TipRanks
Follow Us
AxoGen (AXGN)
NASDAQ:AXGN
AXGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.59 - $21.00
Previous CloseN/A
Volume66.42K
Average Volume (3M)620.80K
Market Cap
$499.62M
Enterprise ValueN/A
Total Cash (Recent Filing)$33.48M
Total Debt (Recent Filing)$68.69M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 06, 2025EPS Estimate
0.06Last Dividend Ex-Date
Jan 27, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding45,544,044
10 Day Avg. Volume431,130
30 Day Avg. Volume620,801
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)7.93
Price to Sales (P/S)0.00
P/FCF Ratio630.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$24.00Price Target Upside120.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
AxoGen News
PremiumCompany Announcements
AxoGen’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Axogen Reports Strong Q1 2025 Revenue GrowthBulls Say, Bears Say
Bulls Say
Market StrategyAxogen is building the foundation to be a consistent 15-20% grower with line of sight to significant operating leverage and improving profitability.
Product DemandHPAs performed well during the quarter with +5% year-over-year active HPA growth and +24% year-over-year HPA productivity growth, suggesting robust demand for the AXGN portfolio of products.
Sales GrowthManagement noted +17% y/y revenue growth was driven by enhanced sales productivity and commercial execution, which provides incremental confidence in the +15-20% LRP revenue CAGR.
Bears Say
Earnings ExpectationsLower-than-expected gross and Adjusted EBITDA in 1Q25 margin may prompt investor questions.
Gross MarginGross margin missed the estimate due to higher manufacturing costs at their new facility, with lower overhead absorption and higher reserves/write-offs impacting COGS.
Leadership ChangesThe 23% sell-off is attributed to disappointing gross margin, unexpected inventory write-offs, the departure of CFO Nir Naor, and slower-than-expected breast sales specialist hiring.
Ownership Overview
2.55% Insiders
17.53% Mutual Funds
37.64% Other Institutional Investors
28.36% Public Companies and Individual Investors
AXGN FAQ
What was AxoGen’s price range in the past 12 months?
AxoGen lowest stock price was $6.59 and its highest was $21.00 in the past 12 months.
What is AxoGen’s market cap?
AxoGen’s market cap is $499.62M.
When is AxoGen’s upcoming earnings report date?
AxoGen’s upcoming earnings report date is Aug 06, 2025 which is in 61 days.
How were AxoGen’s earnings last quarter?
AxoGen released its earnings results on May 08, 2025. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of $0.015 by -$0.035.
Is AxoGen overvalued?
According to Wall Street analysts AxoGen’s price is currently Undervalued.
Does AxoGen pay dividends?
AxoGen pays a Notavailable dividend of $1 which represents an annual dividend yield of N/A. See more information on AxoGen dividends here
What is AxoGen’s EPS estimate?
AxoGen’s EPS estimate is 0.06.
How many shares outstanding does AxoGen have?
AxoGen has 45,544,044 shares outstanding.
What happened to AxoGen’s price movement after its last earnings report?
AxoGen reported an EPS of -$0.02 in its last earnings report, missing expectations of $0.015. Following the earnings report the stock price went down -23.185%.
Which hedge fund is a major shareholder of AxoGen?
Currently, no hedge funds are holding shares in AXGN
AxoGen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.00 (120.18% Upside)
$24.00 (120.18% Upside)
Blogger Sentiment
Bullish
AXGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 280.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $254.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.56%
12-Months-Change
Fundamentals
Return on Equity
-7.22%
Trailing 12-Months
Asset Growth
5.17%
Trailing 12-Months
Company Description
AxoGen
AxoGen, Inc. (AXGN) is a regenerative medicine company specializing in the development and commercialization of innovative solutions for peripheral nerve injuries. The company's primary focus is on creating advanced surgical implants and allografts to repair damaged nerves, providing surgeons with tools to improve patient outcomes. AxoGen operates within the biotechnology and medical device sectors, with its core products including nerve repair technologies such as Avance Nerve Graft, AxoGuard Nerve Connector, and AxoGuard Nerve Protector, all designed to aid in nerve regeneration and functional recovery.
AXGN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic advancements, particularly in high-potential accounts and the BLA process for Avance Nerve Graft. However, challenges such as a decline in gross margin, delayed hiring for the breast segment, and the inability to implement process improvements until after BLA approval were noted. Overall, the positive aspects, including revenue growth and strategic execution, outweigh the challenges.Read More>AXGN Stock 12 Month Forecast
Average Price Target
$24.00
▲(120.18%Upside)